Niemann-Pick disease treatment: A systematic review of clinical trials

Annals of Translational Medicine

Volumn 3, Issue 22, 2015, Pages

  Santos Lozano, Alejandro ^a,b   García, Diana Villamandos ^c   Sanchis Gomar, Fabian ^a   Fiuza Luces, Carmen ^a   Pareja Galeano, Helios ^a   Garatachea, Nuria ^a,d   Gadea, Gisela Nogales ^e   Lucia, Alejandro ^a,f  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b EUROPEAN UNIVERSITY MIGUEL DE CERVANTES   (Spain)

^c UNIVERSITY OF LEÓN   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

Clinical trial; Miglustat; Niemann Pick (NP) disease; Treatment

Indexed keywords

EID: 85015494760     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.12.04     Document Type: Review

References (35)

1. Stern G. Niemann-Pick's and Gaucher's diseases. Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S143-6.
2. Pérez-Sala D, Boya Tremoleda P, Stamatakis K. Use of a protein sequence of localisation and endolysosomal degradation. Available online: http://digital.csic.es/bitstream/10261/27861/1/WO2010034870A1.pdf
3. Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000.
4. Guadalupe JT, Fabiola OP, David IG. Enfermedad de Niemann-Pick tipo C. Revista Mexicana de Neurociencia Septiembre-Octubre 2012;13:281-5.
5. Wang RY, Bodamer OA, Watson MS, et al. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med 2011;13:457-84.
6. Crocker AC. The cerebral defect in Tay-Sachs disease and Niemann-Pick disease. J Neurochem 1961;7:69-80.
7. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010;5:16.
8. Brady RO, Kanfer JN, Mock MB, et al. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proc Natl Acad Sci U S A 1966;55:366-9.
9. Thurberg BL, Wasserstein MP, Schiano T, et al. Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B). Am J Surg Pathol 2012;36:1234-46.
10. McGovern MM, Wasserstein MP, Giugliani R, et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 2008;122:e341-9.
11. Marfa MP. Enfermedad de Niemann-Pick C. Barcelona: Publicaciones Permanyer, 2012.
12. Pineda M, Perez-Poyato MS, O'Callaghan M, et al. Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series. Mol Genet Metab 2010;99:358-66.
13. Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 2010;99:351-7.
14. NP-C Guidelines Working Group, Wraith JE, Baumgartner MR, et al. Recommendations on the diagnosis and management of Niemann-Pick disease type C. Mol Genet Metab 2009;98:152-65.
15. The GeneCards Human Gene Database. Available online: http://www.genecards.org/cgi-bin/carddisp.pl?gene=NPC2&search=NPC2
16. Alavi A, Nafissi S, Shamshiri H, et al. Identification of mutation in NPC2 by exome sequencing results in diagnosis of Niemann-Pick disease type C. Mol Genet Metab 2013;110:139-44.
17. Héron B, Valayannopoulos V, Baruteau J, et al. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis 2012;7:36.
18. Wraith JE, Guffon N, Rohrbach M, et al. Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study. Mol Genet Metab 2009;98:250-4.
19. Wraith JE, Imrie J. New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag 2009;5:877-87.
20. Pineda M, Wraith JE, Mengel E, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study. Mol Genet Metab 2009;98:243-9.
21. Matsuo M, Togawa M, Hirabaru K, et al. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Mol Genet Metab 2013;108:76-81.
22. Abel LA, Bowman EA, Velakoulis D, et al. Saccadic eye movement characteristics in adult Niemann-Pick Type C disease: relationships with disease severity and brain structural measures. PLoS One 2012;7:e50947.
23. Lyseng-Williamson KA. Miglustat: a review of its use in Niemann-Pick disease type C. Drugs 2014;74:61-74.
24. Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6:765-72.
25. Masciullo M, Santoro M, Modoni A, et al. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up. J Inherit Metab Dis 2010;33 Suppl 3:S355-61.
26. Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 2011;34:991-1001.
27. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41.
28. Patterson MC, Di Bisceglie AM, Higgins JJ, et al. The effect of cholesterol-lowering agents on hepatic and plasma cholesterol in Niemann-Pick disease type C. Neurology 1993;43:61-4.
29. Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol 2010;25:300-5.
30. Fecarotta S, Romano A, Della Casa R, et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet J Rare Dis 2015;10:22.
31. Chien YH, Peng SF, Yang CC, et al. Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C. J Inherit Metab Dis 2013;36:129-37.
32. Ginocchio VM, D'Amico A, Bertini E, et al. Efficacy of miglustat in Niemann-Pick C disease: a single centre experience. Mol Genet Metab 2013;110:329-35.
33. Galanaud D, Tourbah A, Lehéricy S, et al. 24 monthtreatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol Genet Metab 2009;96:55-8.
34. Amiri M, Naim HY. Miglustat-induced intestinal carbohydrate malabsorption is due to the inhibition of α-glucosidases, but not β-galactosidases. J Inherit Metab Dis 2012;35:949-54.
35. Santos ML, Raskin S, Telles DS, et al. Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil. J Inherit Metab Dis 2008;31 Suppl 2:S357-61.